We report a precision measurement of the parity-violating asymmetry A_{PV} in the elastic scattering of longitudinally polarized electrons from ^{208}Pb. We measure A_{PV}=550±16(stat)±8(syst) parts per billion, leading to an extraction of the neutral weak form factor F_{W}(Q^{2}=0.00616 GeV^{2})=0.368±0.013. Combined with our previous measurement, the extracted neutron skin thickness is R_{n}-R_{p}=0.283±0.071 fm. The result also yields the first significant direct measurement of the interior weak density of ^{208}Pb: ρ_{W}^{0}=-0.0796±0.0036(exp)±0.0013(theo) fm^{-3} leading to the interior baryon density ρ_{b}^{0}=0.1480±0.0036(exp)±0.0013(theo) fm^{-3}. The measurement accurately constrains the density dependence of the symmetry energy of nuclear matter near saturation density, with implications for the size and composition of neutron stars.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1103/PhysRevLett.126.172502 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
An accelerator-based neutron source design with a thermal neutron port and an epithermal neutron port for boron neutron capture therapy.
Appl Radiat Isot
December 2024
Institute of Nuclear Techniques of Budapest University of Technology and Economics, Műegyetem Rkp 9, 1111, Budapest, Hungary.
This study presents a compact accelerator-driven neutron source design with a thermal neutron port and an epithermal neutron port for Boron Neutron Capture Therapy (BNCT), based on 10 mA 2.5 MeV protons bombarding on a 100 μm thick disc-shaped Li target with a diameter of 10 cm. The moderator consists of 2 parts, the epithermal neutron moderator and the thermal neutron moderator.
View Article and Find Full Text PDFDose optimization of extended collimators in boron neutron capture therapy.
Biomed Phys Eng Express
December 2024
Shandong Key Laboratory of Neutron Science and Technology, International Academy of Neutron Science, Qingdao 266199, People's Republic of China.
In this paper, we propose the design of extending collimators aimed at reducing the radiation dose received by patients with normal tissues and protecting organs at risk in Boron Neutron Capture Therapy (BNCT). Three types of extended collimators are studied: Type 1, which is a traditional design; Type 2, which is built upon Type 1 by incorporating additional polyethylene material containing lithium fluoride (PE(LiF)); Type 3, which adds lead (Pb) to Type 1. We evaluated the dose distribution characteristics of the above-extended collimators using Monte Carlo methods simulations under different configurations: in air, in a homogeneous phantom, and a humanoid phantom model.
View Article and Find Full Text PDFAutomated robotic-assisted patient positioning method and dosimetric impact analysis for boron neutron capture therapy.
Sci Rep
November 2024
Neuboron Therapy System Ltd, Xiamen, Fujian Province, P.R. China.
Boron Neutron Capture Therapy (BNCT) represents a revolutionary approach in targeted radiation treatment for cancer. While the therapy's potential in precise targeting is well-recognized, a critical bottleneck remains in the accurate positioning of patients for treatment delivery. This study proposes a novel automated robotic-assisted patient positioning system specifically engineered for BNCT applications.
View Article and Find Full Text PDFBoron neutron capture therapy for cutaneous angiosarcoma and malignant melanoma: First in-human phase I clinical trial.
Radiother Oncol
January 2025
Department of Radiation Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku Tokyo, 104-0045, Japan; Division of Research and Development for Boron Neutron Capture Therapy, National Cancer Center Exploratory Oncology Research & Clinical Trial Center, 5-1-1 Tsukiji, Chuo-ku Tokyo, 104-0045, Japan. Electronic address:
Background And Purpose: Definitive radiotherapy for patients with scalp angiosarcoma has a poor prognosis, often resulting in severe skin adverse events. Additionally, malignant melanoma is known for its radioresistant nature. Boron neutron capture therapy (BNCT) may address these challenges due to the high uptake capacity of boron drugs in these cancer types.
View Article and Find Full Text PDFComparative Study of Cytotoxicity and Accumulation of Boron and Lithium-Containing Drugs in Skin Melanoma Cells In Vitro.
Bull Exp Biol Med
October 2024
Budker Institute of Nuclear Physics, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia.
We studied cytotoxicity and accumulation of boron and lithium by cultured human fibroblasts and human and mouse skin melanoma cell cultures. The cytotoxicity of boron and lithium drugs was assessed by MTT tests in the boron and lithium concentration range of 10-640 μg/ml. Cell viability was significantly reduced after incubation with boron and lithium at concentrations >160 μg/ml.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!